Bristol-Myers Squibb Inks Licensing Deal With Nissan Chemical And Teijin Pharma For Atrial Fibrillation Compound
This article was originally published in PharmAsia News
Executive Summary
Bristol-Myers Squibb signed a licensing agreement with Tokyo-based Nissan Chemical Industries and Teijin Pharma March 4, which gives BMS worldwide rights, excluding Japan, to develop and market atrial fibrillation compound NTC-801, currently in Phase I in Japan